05 June 2013
S.Fyodorov Eye Microsurgery Complex Federal State Institution and NovaMedica (a pharmaceutical subsidiary of RUSNANO and Domain Associates) have signed an agreement that covers cooperation on localization of innovative ophthalmic products and technologies sourced from around the globe to be developed and produced in Russia.
Prescription drugs with nanotechnology. Americans to build a pharmaceutical plant in Kaluga
28 May 2013
NovaMedica, a joint venture of Domain Associates and RusnanoMedInvest, will complement the pharmaceutical cluster in Kaluga region. A projected plant will be specializing in the manufacturing of therapeutics and medicines for kids. The plant’s capacity is 200 Mio tablets and 5 Mio ampules a year.
27 May 2013
“NovaMedica, LLC plans to build a plant at the site of Kaluga pharmaceutical cluster”, - told Vladimir Gurdus, Team Drive (project managing company) member of the Board while present at the Russian pharmaceutical forum, organized by Adam Smith Institute.
Russian investment vehicle sets sights on innovative drugs
29 March 2013
Russian state-owned nanotechnology giant Rusnano is hoping to break into the pharmaceutical sector with sizeable investments in firms seeking to produce innovative drugs. Rusnano has been ploughing hundreds of millions of dollars into pioneering pharma companies with the aim of growing Russia’s domestic drug production, and making a tidy return by licensing drugs to foreign partners.
Russia is becoming a player in global biopharma
04 February 2013
A biotechnology revolution is gathering steam in Russia, spurred by state investment programs, a host of cross-border partnerships and a domestic market that international investors find highly attractive. The government is modernizing a decaying healthcare system by building new hospitals and introducing innovative technologies.
Russia fund in consortium to back U.S. pharma firms
20 December 2012
Russian state technology firm Rusnano, alongside a group of investors, is investing $93 million in three U.S.-based pharmaceutical firms to develop drugs to treat illnesses such as epilepsy, the investors said on Wednesday.
There is practically no venture financing institution in the field of Life Sciences in Russia
07 August 2012
In the interview to Farmatsevticheskiy Vestnik, Leonid Melamed, Team Drive Chairman of the Board of Directors said that the company having undertaken a venture project in the Russian pharmaceutical market had to act as a pioneer.
Venture capital spurs Russian drug development – in California
25 July 2012
When the Kremlin invited a group of US venture capitalists to Russia during the financial crisis, some of the visitors saw as much an opportunity to scout for fresh sources of capital as they did a new place to invest in.
Coda Therapeutics raise additional $20M for series B
25 July 2012
CoDa Therapeutics has raised an additional $20 million from RusnanoMedInvest in a second close of its Series B financing round. This brings the total Series B Round to nearly $40 million following the first close late last year. All current investors, including Domain Associates, GBS Ventures and BioPacificVentures participated. San Diego-based CoDa is a biopharmaceutical company working to develop drug therapies for wounds that do not heal properly, including venous leg and diabetic foot ulcers.
Russia’s Rusnano, Domain Invest $40 Million In San Diego’s CoDa
24 July 2012
Russian Nanotechnologies, the state- run technology holding, and Domain Associates, a U.S. venture fund, are investing about $40 million in San Diego-based biopharmaceutical company CoDa Therapeutics.
05 November 2024
03 November 2024
October 10 – World Mental Health Day
10 October 2024
Siberian State Medical University and Skoltech to start production of bone tissue fillers
22 November 2024
Sechenov University is creating a digital drug reference book
21 November 2024
Skills shortage still holding back pharma's digital transformation: survey
21 November 2024
Trials for Russia’s first CAR-T drug “Utzhefra” have started
20 November 2024